Showing only trials that are Phase 2

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström’s Macroglobulinemia

Understanding the safety and efficacy of a new drug that stops a certain type of protein working

Expected to end: 01/09/2028

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Studying the long-term effects of Ibrutinib in people who were on previous trials for the drug that have now closed

Expected to end: 29/01/2027

Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia (RAINBOW)

Is ibrutinib and rituximab a more effective first-line treatment than the current standard first-line treatment for people with WM?

Expected to end: 01/03/2030

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Testing a new treatment to understand it’s efficacy and the best dose for patients

Expected to end: 31/03/2028

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

Measuring the efficacy of a drug called Iopofosine I131 in patients with WM

Expected to end: 22/12/2026

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Measuring the safety and efficacy of nemtabrutinib, a type of BTK inhibitor

Expected to end: 19/03/2027

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Measuring the safety and efficacy of Acalabrutinib in people with WM

Expected to end: 31/12/2026